A Neonatal amikacin covariate model can be used to predict ontogeny of other drugs eliminated through glomerular filtration in neonates

Pharmaceutical Research

Volumn 31, Issue 3, 2014, Pages 754-767

  De Cock, Roosmarijn F W ^a   Allegaert, Karel ^b   Sherwin, Catherine M T ^c   Nielsen, Elisabet I ^d   De Hoog, Matthijs ^e   Van Den Anker, Johannes N ^e,f   Danhof, Meindert ^a   Knibbe, Catherijne A J ^a,g  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^f CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^g ST ANTONIUS HOSPITAL   (Netherlands)

Author keywords

developmental changes; extrapolation; glomerular filtration rate; neonates; pharmacokinetics

Indexed keywords

AMIKACIN; GENTAMICIN; NETILMICIN; TOBRAMYCIN; VANCOMYCIN;

AMIKACIN COVARIATE MODEL; ARTICLE; BIRTH WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG URINE LEVEL; FEMALE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DEVELOPMENT; KIDNEY FUNCTION; MALE; NEWBORN; NORMAL HUMAN; ONTOGENY; PARAMETERS CONCERNING THE FETUS, NEWBORN AND PREGNANCY; POSTNATAL AGE; POSTNATAL DEVELOPMENT; PREDICTION; PRIORITY JOURNAL;

AMIKACIN; ANTI-BACTERIAL AGENTS; GLOMERULAR FILTRATION RATE; HUMANS; INFANT, NEWBORN; KIDNEY; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

EID: 84895481895     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1197-y     Document Type: Article

References (35)

1. Cuzzolin L, Atzei A, Fanos V. Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety. Expert Opin Drug Saf. 2006;5(5):703-18.
2. 't Jong GW, Vulto AG, de Hoog M, Schimmel KJ, Tibboel D, van den Anker JN. A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics. 2001;108(5):1089-93.
3. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ. 2000;320(7227):79-82.
4. De Cock RF, Piana C, Krekels EH, Danhof M, Allegaert K, Knibbe CA. The role of population PK-PD modelling in paediatric clinical research. Eur J Clin Pharmacol. 2011;67 Suppl 1:5-16.
5. Ince I, de Wildt SN, Tibboel D, Danhof M, Knibbe CA. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today. 2009;14(5-6):316-20.
6. FDA C. Guidance for industry. General considerations for pediatric pharmacokinetic studies for drugs and biological products (Draft Guidance). 1998 [20 February 2013]; Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072114.pdf.
7. FDA C. Guidance for industry. Population pharmacokinetics. 1999; Available from: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072137.pdf.
8. Tod M, Jullien V, Pons G. Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008;47(4):231-43.
9. Smits A, Kulo A, de Hoon JN, Allegaert K. Pharmacokinetics of drugs in neonates: pattern recognition beyond compound specific observations. Curr Pharm Des. 2012;18(21):3119-46.
10. Manolis E, Osman TE, Herold R, Koenig F, Tomasi P, Vamvakas S, et al. Role of modeling and simulation in pediatric investigation plans. Paediatr Anaesth. 2011;21(3):214-21.
11. Bellanti F, Della Pasqua O. Modelling and simulation as research tools in paediatric drug development. Eur J Clin Pharmacol. 2011;67 Suppl 1:75-86.
12. Johnson TN. Modelling approaches to dose estimation in children. Br J Clin Pharmacol. 2005;59(6):663-9.
13. Knibbe CA, Krekels EH, Danhof M. Advances in paediatric pharmacokinetics. Expert Opin Drug Metab Toxicol. 2011;7(1):1-8.
14. Krekels EHJ, Neely M, Panoilia E, Tibboel D, Capparelli E, Danhof M, et al. From pediatric covariate model to semiphysiological function for maturation: part I - extrapolation of a covariate model from morphine to zidovudine. CPT: Pharmacometrics & Systems Pharmacology. 2012;1:e9. doi: 10.1038/psp201211. Published online 3 October 2012.
15. Krekels EHJ, Johnson TN, den Hoedt SM, Rostami-Hodjegan A, Danhof M, Tibboel D, et al. From pediatric covariate model to semiphysiological function for maturation: part II - sensitivity to physiological and physicochemical properties. CPT: Pharmacometrics & Systems Pharmacology. 2012;1:e10. doi: 10.1038/psp201212. Published online 10 October 2012.
16. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, et al. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet. 2012;51(2):105-17.
17. Sherwin CM, Broadbent RS, Medlicott NJ, Reith DM. Individualising netilmicin dosing in neonates. Eur J Clin Pharmacol. 2008;64(12):1201-8.
18. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 1997;62(4):392-9.
19. Allegaert K, Anderson BJ, van den Anker JN, Vanhaesebrouck S, de Zegher F. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther Drug Monit. 2007;29(3):284-91.
20. Sherwin CM, McCaffrey F, Broadbent RS, Reith DM, Medlicott NJ. Discrepancies between predicted and observed rates of intravenous gentamicin delivery for neonates. J Pharm Pharmacol. 2009;61(4):465-71.
21. Nielsen EI, Sandstrom M, Honore PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet. 2009;48(4):253-63.
22. Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA. Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models. Pharm Res. 2011;28(4):797-811.
23. Montgomery DC, Peck EA. Introduction to linear regression analysis. New York: Wiley; 1982. p. 301-2.
24. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin Pharmacol Ther. 2007;82(1):17-20.
25. Allegaert K. The impact of ibuprofen or indomethacin on renal drug clearance in neonates. J Matern Fetal Neonatal Med. 2009;22 Suppl 3:88-91.
26. Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, et al. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J Clin Pharmacol. 2001;41(9):927-34.
27. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077-97.
28. George I, Mekahli D, Rayyan M, Levtchenko E, Allegaert K. Postnatal trends in creatinemia and its covariates in extremely low birth weight (ELBW) neonates. Pediatr Nephrol. 2011;26(10):1843-9.
29. Brendel K, Dartois C, Comets E, Lemenuel-Diot A, Laveille C, Tranchand B, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet. 2007;46(3):221-34.
30. Comets E, Brendel K, Mentre F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Prog Biomed. 2008;90(2):154-66.
31. Pacifici GM, Allegaert K. Clinical pharmacokinetics of vancomycin in the neonate: a review. Clinics (Sao Paulo). 2012;67(7):831-7.
32. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother. 2004;48(4):1159-67.
33. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53-75.
34. Johnson TN, Rostami-Hodjegan A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth. 2011;21(3):291-301.
35. Allegaert K, Smits A, van den Anker JN. Physiologically based pharmacokinetic modeling in pediatric drug development: a clinician's request for a more integrated approach. J Biomed Biotechnol. 2012;103763.